We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 128.26 | 4 | 09:56:45 |
From May 2019 to May 2024
By Colin Kellaher
Merck & Co. on Monday said a phase 3 study evaluating its cancer drug Keytruda in adults with relapsed or refractory classical Hodgkin lymphoma met one of its dual primary endpoints.
The Kenilworth, N.J., drug maker said Keytruda showed a statistically significant and clinically meaningful improvement in progression-free survival compared with the currently approved therapy of brentuximab vedotin.
Merck said the other primary endpoint of overall survival wasn't formally tested at this interim analysis per the study's pre-specified analysis plan.
Merck said Keytruda's safety profile was consistent with previous studies, with no new safety signals identified.
The U.S. Food and Drug Administration in March 2017 approved Keytruda for adults and pediatric patients with refractory classical Hodgkin lymphoma, or who have relapsed after three or more prior lines of therapy. The company said the latest study data are strongly supportive of Keytruda's current indication.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 02, 2020 07:08 ET (12:08 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
